Patient characteristics
| Patients (gender) . | Age (y) . | Original disease . | Disease status at time of HSCT . | Conditioning regimen . | Duration of study monitoring (days from HSCT) . | CMV serological status (D/R) . | CMV reactivation (first day post-HSCT) . | Status . |
|---|---|---|---|---|---|---|---|---|
| Pt #1 (F) | 17 | BCP-ALL | Second CR | TBI/TT/L-PAM | 215 | +/− | — | Alive |
| Pt #2 (M) | 8 | BCP-ALL | Second CR | TBI/TT/CY | 214 | −/+ | — | Alive |
| Pt #3 (M) | 2 | SCID | NA | TREO/FLU | 512 | +/+ | + (9) | Alive |
| Pt #4 (F) | 11 | AML | First CR | TREO/TT/FLU | 200 | +/+ | + (30) | Alive |
| Pt #5 (M) | 10 | T-ALL | First CR | TBI/TT/FLU | 198 | +/− | + (17) | Alive |
| Pt #6 (F) | 13 | BCP-ALL | Second CR | TBI/TT/FLU | 193 | +/+ | + (27) | Alive |
| Pt #7 (F) | 10 | BCP-ALL | Second CR | TBI/TT/FLU | 216 | +/− | + (30) | Alive |
| Pt #8 (M) | 1 | SCID | NA | TREO/TT/FLU | 240 | +/− | + (13) | Alive |
| Pt #9 (M) | 6 | AML | First CR | BU/CY/L-PAM | 233 | +/+ | + (35) | Alive |
| Pt #10 (M) | 14 | AML | First CR | TBI/TT/FLU | 305 | +/+ | + (13) | Alive |
| Pt #11 (M) | 2 | SDS | NA | TREO/TT/FLU | 370 | +/+ | — | Alive |
| Pt #12 (M) | 7 | T-ALL | Second CR | TBI/TT/FLU | 130 | +/+ | — | Dead because of disease recurrence |
| Pt #13 (F) | 13 | BCP-ALL | Refractory disease | TBI/TT/FLU | 97 | +/− | — | Dead because of disease recurrence |
| Pt #14 (M) | 6 | AML | Refractory disease | TBI/TT/L-PAM | 55 | +/+ | + (37) | Dead because of disease recurrence |
| Pt #15 (M) | <1 | SCID | NA | TREO/FLU | 363 | +/+ | + (14) | Alive |
| Pt #16 (F) | 6 | Fanconi anemia | NA | TBI/CY/FLU | 140 | −/− | — | Alive |
| Pt #17 (M) | 3 | Hyper-IgE syndrome | NA | BU/TT/FLU | 91 | +/+ | — | Alive |
| Pt #18 (M) | 17 | Refractory cytopenia of childhood | Disease present | TREO/TT/FLU | 230 | +/+ | — | Alive |
| Pt #19 (F) | 7 | AML | First CR | BU/TT/FLU | 54 | +/+ | + (8) | Dead because of AdV infection |
| Pt #20 (F) | 1 | Osteopetrosis | NA | BU/FLU | 210 | −/− | — | Alive |
| Pt #21 (M) | 13 | Refractory cytopenia of childhood | Disease present | TREO/TT/FLU | 127 | +/+ | — | Alive |
| Pt #22 (F) | 5 | Fanconi anemia | NA | TBI/CY/FLU | 120 | +/+ | — | Alive |
| Pt #23 (F) | 6 | BCP-ALL | Third CR | TREO/TT/L-PAM | 98 | +/+ | + (28) | Dead because of disease recurrence |
| Pt #24 (F) | <1 | SCID | NA | TREO/FLU | 207 | +/+ | — | Alive |
| Pt #25 (M) | 2 | AML | First CR | BU/CY/L-PAM | 217 | +/+ | + (7) | Alive |
| Pt #26 (F) | <1 | ALL | First CR | BU/TT/FLU | 111 | +/+ | + (19) | Alive |
| Pt #27 (M) | 3 | Kostmann syndrome | NA | TREO/TT/FLU | 236 | +/+ | + (28) | Alive |
| Patients (gender) . | Age (y) . | Original disease . | Disease status at time of HSCT . | Conditioning regimen . | Duration of study monitoring (days from HSCT) . | CMV serological status (D/R) . | CMV reactivation (first day post-HSCT) . | Status . |
|---|---|---|---|---|---|---|---|---|
| Pt #1 (F) | 17 | BCP-ALL | Second CR | TBI/TT/L-PAM | 215 | +/− | — | Alive |
| Pt #2 (M) | 8 | BCP-ALL | Second CR | TBI/TT/CY | 214 | −/+ | — | Alive |
| Pt #3 (M) | 2 | SCID | NA | TREO/FLU | 512 | +/+ | + (9) | Alive |
| Pt #4 (F) | 11 | AML | First CR | TREO/TT/FLU | 200 | +/+ | + (30) | Alive |
| Pt #5 (M) | 10 | T-ALL | First CR | TBI/TT/FLU | 198 | +/− | + (17) | Alive |
| Pt #6 (F) | 13 | BCP-ALL | Second CR | TBI/TT/FLU | 193 | +/+ | + (27) | Alive |
| Pt #7 (F) | 10 | BCP-ALL | Second CR | TBI/TT/FLU | 216 | +/− | + (30) | Alive |
| Pt #8 (M) | 1 | SCID | NA | TREO/TT/FLU | 240 | +/− | + (13) | Alive |
| Pt #9 (M) | 6 | AML | First CR | BU/CY/L-PAM | 233 | +/+ | + (35) | Alive |
| Pt #10 (M) | 14 | AML | First CR | TBI/TT/FLU | 305 | +/+ | + (13) | Alive |
| Pt #11 (M) | 2 | SDS | NA | TREO/TT/FLU | 370 | +/+ | — | Alive |
| Pt #12 (M) | 7 | T-ALL | Second CR | TBI/TT/FLU | 130 | +/+ | — | Dead because of disease recurrence |
| Pt #13 (F) | 13 | BCP-ALL | Refractory disease | TBI/TT/FLU | 97 | +/− | — | Dead because of disease recurrence |
| Pt #14 (M) | 6 | AML | Refractory disease | TBI/TT/L-PAM | 55 | +/+ | + (37) | Dead because of disease recurrence |
| Pt #15 (M) | <1 | SCID | NA | TREO/FLU | 363 | +/+ | + (14) | Alive |
| Pt #16 (F) | 6 | Fanconi anemia | NA | TBI/CY/FLU | 140 | −/− | — | Alive |
| Pt #17 (M) | 3 | Hyper-IgE syndrome | NA | BU/TT/FLU | 91 | +/+ | — | Alive |
| Pt #18 (M) | 17 | Refractory cytopenia of childhood | Disease present | TREO/TT/FLU | 230 | +/+ | — | Alive |
| Pt #19 (F) | 7 | AML | First CR | BU/TT/FLU | 54 | +/+ | + (8) | Dead because of AdV infection |
| Pt #20 (F) | 1 | Osteopetrosis | NA | BU/FLU | 210 | −/− | — | Alive |
| Pt #21 (M) | 13 | Refractory cytopenia of childhood | Disease present | TREO/TT/FLU | 127 | +/+ | — | Alive |
| Pt #22 (F) | 5 | Fanconi anemia | NA | TBI/CY/FLU | 120 | +/+ | — | Alive |
| Pt #23 (F) | 6 | BCP-ALL | Third CR | TREO/TT/L-PAM | 98 | +/+ | + (28) | Dead because of disease recurrence |
| Pt #24 (F) | <1 | SCID | NA | TREO/FLU | 207 | +/+ | — | Alive |
| Pt #25 (M) | 2 | AML | First CR | BU/CY/L-PAM | 217 | +/+ | + (7) | Alive |
| Pt #26 (F) | <1 | ALL | First CR | BU/TT/FLU | 111 | +/+ | + (19) | Alive |
| Pt #27 (M) | 3 | Kostmann syndrome | NA | TREO/TT/FLU | 236 | +/+ | + (28) | Alive |
All patients were given rabbit anti-T cell globulin from day −5 to day −3 and rituximab (200 mg/m2 on day −1). No pharmacologic prophylaxis of GVHD was administered after transplantation.
AdV, adenovirus; BCP-ALL, B-cell precursor ALL; BU, busulfan; CR, complete remission; CY, cyclophosphamide; D, donor; F, female; FLU, fludarabine; L-PAM, melphalan; M, male; NA, not applicable; R, recipient; SCID, severe combined immunodeficiency; SDS, Shwachman-Diamond syndrome; T-ALL, T-cell ALL; TBI, total body irradiation; TREO, treosulfan; TT, thiotepa.